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ABSTRACT
Splice-switching antisense oligonucleotides (ASOs),
which bind specific RNA-target sequences and mod-
ulate pre-mRNA splicing by sterically blocking the
binding of splicing factors to the pre-mRNA, are a
promising therapeutic modality to treat a range of
genetic diseases. ASOs are typically 15–25 nt long
and considered to be highly specific towards their in-
tended target sequence, typically elements that con-
trol exon definition and/or splice-site recognition.
However, whether or not splice-modulating ASOs
also induce hybridization-dependent mis-splicing of
unintended targets has not been systematically stud-
ied. Here, we tested the in vitro effects of splice-
modulating ASOs on 108 potential off-targets pre-
dicted on the basis of sequence complementarity,
and identified 17 mis-splicing events for one of the
ASOs tested. Based on analysis of data from two
overlapping ASO sequences, we conclude that off-
target effects are difficult to predict, and the choice of
ASO chemistry influences the extent of off-target ac-
tivity. The off-target events caused by the uniformly
modified ASOs tested in this study were significantly
reduced with mixed-chemistry ASOs of the same se-
quence. Furthermore, using shorter ASOs, combin-
ing two ASOs, and delivering ASOs by free uptake
also reduced off-target activity. Finally, ASOs with
strategically placed mismatches can be used to re-
duce unwanted off-target splicing events.
INTRODUCTION
Antisense oligonucleotides (ASOs) are a powerful re-
search and therapeutic tool for a diverse range of appli-
cations, including target knock-down, splice correction,
reading-frame restoration, removal of missense mutations,
translational inhibition andmodulating nonsense-mediated
mRNA decay (NMD) (1,2). The mechanism of action of
therapeutic ASOs depends on the type and position of
chemical modifications in the phosphate backbone, ribose
sugar and bases (3). Given that ASOs bind to RNA tar-
get sites by Watson–Crick base pairing, their specificity is
primarily determined by the sequence itself. The sequence
specificity of unmodified DNA oligos injected into Xeno-
pus oocytes was investigated early on (4).Mismatches to the
target sequence were shown to be tolerated, and the authors
concluded that nonspecific RNA targets are likely partially
degraded, which may be tolerated during oocyte develop-
ment in most cases (4). However, with improvements in
ASO chemistries with higher affinity for RNA, such as
second- and third-generation 2’-O-methoxyethyl (MOE),
2’, 4’-constrained 2’-O-ethyl (cEt) and locked nucleic acid
(LNA) modifications, extensive sequence complementar-
ity may not be required for efficient target engagement.
This property is especially relevant for RNase-H-mediated
knockdown with ‘gapmer’ ASOs. Gapmer sequences typi-
cally consist of 8–10 DNA nucleotides flanked by 3–5 mod-
ified high-affinity nucleotide ‘wings’ (5). Upon binding to
RNA, the DNA/RNA duplex is recognized by RNase H,
resulting in cleavage and degradation of the RNA strand.
Importantly, cleavage requires as few as five continuous
base pairs (6), which could result in knock-down of partially
hybridized targets. Even thoughmismatch-induced changes
in the shape of the RNA/DNA duplex negatively affect
RNase-H-mediated cleavage (7), hybridization-dependent
knock-down of unintended targets with mismatches was
demonstrated in vitro (8), and is associated with hepato-
toxicity in vivo (9). Assessment of off-targets, both in sil-
ico and experimentally, has therefore been recommended as
an important part of the antisense drug-discovery process
(10,11).
For splice-modulating ASOs, even fully complementary
binding to the target sequence is not always sufficient to
elicit an effect. ASOs typically target short regulatory el-
ements in introns and exons (splicing enhancers and si-
lencers) or the splice sites directly, to sterically interfere with
the binding of proteins or small RNAs involved in splic-
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ing (12). ASOs that bind just one or a few nucleotides up-
stream or downstream of these regulatory sites sometimes
completely lack splice-switching activity, as is often evident
in ASO walks along the target sequence of interest (13–15).
Steric-blocking ASOs are typically uniformly modified to
prevent RNase-H-mediated cleavage, and as a result, they
usually have high affinity for RNA. However, even if ASOs
bind to partially complementary sequences in unintended
targets, aberrant splicing as a result of this interaction is
likely rare, and has not been studied extensively. In a study
in which three potential splicing-specific off-targets were
considered, none were experimentally identified (16). One
reason could be that the BLAST algorithm commonly used
for identifying ASO sequence complementarity heavily pe-
nalizes gaps and bulges, and does not consider G:U wobble
base-pairing, typically found in RNA structures (17). The
extent of ASO-mediated mis-splicing of unintended targets
could therefore be more common than previously expected,
warranting a more detailed investigation.
In this study, we investigate sequence-specific off-target
effects of splice-switching ASOs in vitro and in vivo. The
two overlapping ASO sequences used here were previously
shown to target an exonic splicing enhancer (ESE) in exon
10 of the PKM gene, which results in an isoform switch
from PKM2 to PKM1 (14,18). We adapted RNAhybrid,
a microRNA target-prediction tool, to identify sequence
complementarities between the ASO and the human tran-
scriptome. We then tested 108 potential ASO targets by
RT-PCR, and identified 17 mis-splicing events for one of
the ASOs tested, some of which were unexpectedly stronger
than the on-target activity on PKM splicing. We also found
that the choice of ASO chemistry has a strong influence
in the extent of off-target activity, with cEt/DNA mixed-
chemistry ASOs having greater specificity than uniformly
modified MOE ASOs. Furthermore, shortening the ASO
sequence, using two ASOs in combination at lower con-
centration, introducing targeted mismatches, and deliver-
ing ASOs by free uptake rather than transfection, also re-
duced off-target activity. In summary, ASOs targeting spe-
cific RNA motifs to modulate splicing can also cause de-
tectable levels of off-target mis-splicing, which theoretically
could contribute to potential ASO toxicities in vitro or in
vivo.
MATERIALS AND METHODS
Identifying potential ASO target sites in the transcriptome
We generated an in silico library of exons, including ±200
nt of flanking sequence, for all principal and alternative
isoforms (APPRIS database (19)) of protein-coding tran-
scripts in the GRCh38/hg38 human genome assembly, and
assigned unique identifiers (Unique ID) to each entry. We
removed duplicate exon coordinates (arising from overlap-
ping transcripts) to speed up the alignment process. The
resulting in silico exon library served as a reference for
RNAhybrid sequence alignment (20), which we used to
identify the top two ASO-binding sites in each exon/intron,
based on binding free energy. Importantly, we allowed gaps,
loops, and G:U base-pairing, which were part of the mini-
mum free energy (MFE) calculation for each ASO-target
pair. We selected the following settings: maximum inter-
nal loop length and bulge size were set to 5 nt each, and
the free energy threshold was variable depending on the
ASO, but was at least 10 kcal/mol lower than the on-target
binding free energy. We did not set helix constraints, and
chose the compact output to help with data formatting. We
then annotated target sequences for each exon with gene
names, exon position (terminal, internal), strand informa-
tion, MFE, number of mismatches, number of G:U base
pairs, binding site (exon, intron, splice site), distance to the
closest splice site, and whether the exon is part of the cod-
ing sequence or UTR. We also analyzed ASO target se-
quences for potential binding sites of RNA-binding pro-
teins using the RBPmap online tool (rbpmap.technion.ac.il
(21)). RNA-binding proteins included in this analysis were
HNRNP-A1, -A2B1, -C, -F, -H1, -H2, -M, SNRNP70,
SNRPA, SRSF1, SRSF2, SRSF3, SRSF5, SRSF6, SRSF7,
SRSF9, SRSF10, TRA2A, TRA2B andU2AF2.We set the
stringency level to ‘high’, and the conservation filter to ‘on’.
Lastly, we obtained RNA expression levels (TPM) of the
predicted targets for common human cell lines and tissues
from The Protein Atlas (proteinatlas.org (22)), and added
them to the results table.
Antisense oligonucleotides
All ASOs used in this study are listed in Table 1. 2’-O-
methoxyethyl (MOE) synthesis, purification, and quantifi-
cation were performed as described (23). Mixed-chemistry
oligonucleotides were a mixture of constrained ethyl (cEt)
and DNA, as shown in Table 1, and were synthesized as
described (24). All ASOs had uniform phosphorothioate
(PS) backbones and 5-methyl C. We dissolved the ASOs in
water and stored them at −20◦C. Oligonucleotide concen-
tration was determined with a Nanodrop spectrophotome-
ter. RNA-oligos used for Tmmeasurements were purchased
from IDT.
Cell culture and ASO delivery
U87 MG glioblastoma cells and HT-1080 fibrosarcoma
cells were maintained in DMEM supplemented with 10%
FBS and 1% penicillin and streptomycin. HepG2 cells were
cultured in EMEM supplemented with 10% FBS and 1%
penicillin and streptomycin.We delivered ASOs to U87 and
HepG2 cells using Lipofectamine 2000 (Invitrogen) at a fi-
nal concentration of 30 nM. Alternatively, we added ASOs
directly to the culture medium without transfection agent
(free uptake), at the indicated concentrations, for up to 5
days.
Primer design and PCR
Total RNA was extracted using Trizol reagent, and
reverse-transcribed with ImProm-II reverse transcriptase
(Promega), using oligo-dT primers. PKM cDNA was am-
plified with AmpliTaq DNA polymerase (Thermo Fisher)
using exon 8 Fwd 5’-AGAAACAGCCAAAGGGGACT-
3’ and exon 11 Rev 5’-CATTCATGGCAAAGTTCACC-
3’ primers. The PCR product was digested with PstI for 2
h at 37◦C to distinguish PKM1 (undigested) from PKM2
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Table 1. ASOs used in this study
ASO name IONIS # Length Sequence 5’-3’ Chemistry
ASO1-MOE 5644676 18 nt CGGCGGAGTTCCTCAAAT Uniform MOE
ASO1-cEt/DNA 742114 18 nt CGGCGGAGTTCCTCAAAT kkddkddkddkddkddkk
ASO1-MOE/DNA 759514 18 nt CGGCGGAGTTCCTCAAAT eeddeddeddeddeddee
ASO2-MOE 564472 18 nt AGGCGGCGGAGTTCCTCA Uniform MOE
ASO2-cEt/DNA 872245 18 nt AGGCGGCGGAGTTCCTCA kkddkddkddkddkddkk
GN3-ASO2-MOE 1057288 18 nt AGGCGGCGGAGTTCCTCA 5’-GalNAc3-Uniform MOE
GN3-ASO2-cEt/DNA 950663 18 nt AGGCGGCGGAGTTCCTCA 5’-GalNAc3-kkddkddkddkddkddkk
GN3-SMN-MOE 699819 20 nt ATTCACTTTCATAATGCTGG 5’-GalNAc3-Uniform MOE
Ctrl. ASO-MOE (M4) 759518 18 nt CGGATGAGTGCCTGCAAT Uniform MOE
Ctrl. ASO-cEt/DNA (M4) 872243 18 nt CGGATGAGTGCCTGCAAT kkddkddkddkddkddkk
Scr. Ctrl ASO 742116 18 nt GCTGATCCGAGTAAGCTC Uniform MOE
12mer MOE 759513 12 nt CGGCGGAGTTCC Uniform MOE
I9-MOE 461378 15 nt TACCTGCCCTTAGGG Uniform MOE
e: 2’-O-methoxyethyl (MOE) base modification; k: constrained ethyl (cEt) base modification; d: DNA base; GN3: tri-antennary N-acetyl galactosamine;
all ASOs have a uniform PS backbone and 5-methyl-C modifications.
(2 bands) (14). Primers used to test the effect of ASOs on
potential off-targets are listed in Supplementary Table S1,
and were designed using NCBI Primer-BLAST (25). For-
ward and reverse primers were positioned at least 1 exon up-
stream and downstream, respectively, of the exon predicted
to be bound by the ASO. The primer Tm, GC content,
and product length were similar for all tested off-targets,
and a standard PCR program (55◦C annealing; 25 cycles)
was used for all amplicons. If no band was detected, the
PCR was repeated using 30 cycles. Primers that did not
yield a product or yielded non-specific bands (based on
size) were excluded from the analysis. The [-32P]-dCTP ra-
diolabeled PCR products were separated on a 5% native
polyacrylamide gel, visualized by autoradiography on a Ty-
phoon 9410 phosphoimager (GE Healthcare), and quanti-
fied using Multi Gauge v2.3 (Fujifilm, Tokyo, Japan). The
radioactive signal of each band was normalized to the G/C
content to calculate relative changes in splice isoforms.
Tm measurements
Melting temperatures of RNA/ASO duplexes were deter-
mined by high-resolution melting curves performed on a
QuantStudio 6 Flex Real-Time PCR System (26). Single-
stranded fragments (1–2 M each) were mixed with 6.25
M Eva green (Biotium, Fremont, CA) and annealing
buffer (final concentration 10 mM Tris pH 7.4, 1 mM
EDTA, 50 mMNaCl). 10 L of the sample was transferred
onto 386-well plates for melting analysis. The samples were
heated to 98◦C for 2 min, cooled to 25◦C for 1 min at a
rate of 0.05◦C/s for annealing, and heated to 98◦C at a rate
of 0.05◦C/s formelting analysis (continuousmeasurement).
The Tm of each duplex was measured a total of six times on
two separate plates.
Animals and tumor model
Non-obese diabetic-severe combined immunodeficiency
(NOD-SCID)-gamma (NSG) immunocompromised mice
(strain 005557; The Jackson Laboratory) were housed in
vented cages and bred in-house.ASGP-R1(H1a)-expressing
U87 cells used to generate xenografts are described in
Scharner et al. (27). Tumors were established by inject-
ing 5 × 106 U87-H1a cells (50 000 cells/l in Hank’s Bal-
anced Salt Solution) subcutaneously into the flanks of adult
NSG mice. Once tumors were palpable (7–10 days post-
transplantation), animals were treated with ASOs delivered
by subcutaneous (s.c.) injection at 250mg/kg/week, 5 times
per week for two weeks, before collecting tumor tissue for
splicing analysis. All animal protocols were performed in
accordance with Cold Spring Harbor Laboratory’s Institu-
tional Animal Care and Use Committee (IACUC) guide-
lines.
Statistics and graph representation
Graphs were generated in Microsoft Excel and GraphPad
Prism 6. Figures were compiled using Adobe Illustrator.
Paired Student’s t-test was used to test for statistical dif-
ference between off-target scores; unpaired Student’s t-test
and Fisher’s exact test were used to test for statistical signif-
icance of feature characteristics of off-target sites. P-values
<0.05 were considered to be statistically significant. For
multiple hypotheses testing, P-values less than the Bonfer-
roni critical value (/n; specified in the figure legends) were
considered to be statistically significant.
RESULTS
Identification of ASO sequence complementarities in the hu-
man transcriptome
To investigate whether ASO-mediated off-target splicing
events are detectable in ASO-treated cells, we utilized the
miRNA prediction tool RNAhybrid (20), to detect ASO
sequence complementarities in the transcriptome, while al-
lowing for G:U base pairing, loops, and gaps. We aimed
to identify potential ASO-binding sites on or near exons,
and then test the splicing outcome by RT-PCR. We there-
fore created a database of exon sequences, including up to
200 nt of flanking intronic sequences, in which to search
for putative ASO-binding sites. After aligning the ASO to
the exon database using RNAhybrid, we formatted, anno-
tated, and exported the data for further analysis (Figure
1A). To characterize eachASO-binding site in the transcrip-
tome, we also listed several descriptive features, including
the number of mismatches, the number of G:U base pairs,
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Figure 1. Prediction of off-targets and validation by RT-PCR. (A) ASO sequences were aligned to an exon database, including 200 nt of each flanking
intron. Sequence alignment was performed using RNAhybrid, allowing G:U wobble base pairing, internal loops, and bulges. The data were annotated
and formatted for further analysis. (B) Features used to characterize the interaction between the ASO and the RNA target. (C) Potential off-targets were
tested by radioactive RT-PCR, using primer pairs located at least 1 exon upstream and downstream of the binding site, respectively. Positive hits from the
initial screen were analyzed further. (D) ASOs used in the initial off-target screen included two PKM splice-switching ASOs shifted by three nucleotides
(ASO1-MOE and ASO2-MOE), and a control ASOwith five mismatches to the target (Ctrl ASO-MOE). Nucleotides highlighted in red indicate mismatch
positions. (E) Distribution of the minimum free energy (MFE; kcal/mol) of the top 1000 and top 50 hits from the RNAhybrid alignment prediction. PKM
was the top hit for both ASO1 (−38.2 kcal/mol) and ASO2 (−44.4 kcal/mol). (F) Venn diagrams of overlapping targets among the top 1000 hits. ASO1
and the Ctrl ASO have 13 hits in common. ASO1 and ASO2 have 294 targets in common.
the distance to the nearest splice site, etc. (Figure 1B, Sup-
plementary Table S2). We then selected a wide range of
predicted targets and tested the ASO’s effect on splicing of
the nearest exon in an initial RT-PCR screen. When we de-
tected an aberrant splice product, we further characterized
the splicing event by RT-PCR (Figure 1C). The ASOs used
for the initial screen were two uniformly modified, MOE-
PS PKM splice-switching ASOs targeting exon 10 (ASO1
and ASO2), as well as a control ASO with five mismatches
to the PKM target (Figure 1D, Table 1). The ASO mod-
ifications used increase RNA affinity and do not support
RNase-H-mediated cleavage (12). Upon binding to PKM
exon 10, these ASOs induce a splice switch between two
mutually exclusive exons, promoting exon 10 skipping and
exon 9 inclusion (14,18). We aligned each of the ASOs to
the exon database using RNAhybrid, and ranked the hits
by minimum free energy (MFE). The calculated MFE val-
ues of the top 50 and top 1000 targets shown in Figure 1E
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confirm PKM as the top hit, as well as the only hit with-
out mismatches or G:U wobble base-pairing. For ASO2 we
found a second predicted target with full complementar-
ity (THSD7B); however, 6/18 base pairs are wobble base
pairs, and this gene is not expressed in U87 cells. We also
analyzed the overlap of predicted targets between different
ASOs, and found that a 3-nt shift along the target sequence
changed >70% of the predicted targets, whereas introduc-
ing five mismatches resulted in an almost completely new
set of predicted binding targets (Figure 1F).
PKM splice-switching ASOs induce mis-splicing of some un-
intended targets
To validate predicted off-targets identified by RNAhybrid,
we delivered 30 nM ASO to U87 glioblastoma cells by
lipid transfection, and analyzed RNA splice products by
radioactive RT-PCR 2 days post-transfection. This condi-
tion resulted in 31% and 32% PKM1 splice switching for
MOE-PS modified ASO1 and ASO2, respectively (Figure
2). Importantly, the selected concentration did not saturate
the effect on PKM splice-switching, or result in notable cell
toxicity. (Supplementary Figure S1). We also tested a pair
of cEt and DNA mixed-chemistry ASOs (cEt/DNA) with
the same sequences (Table 1). Mixed-chemistry ASO1 and
ASO2 resulted in 29% and 34% PKM1 splice switching, re-
spectively, at 30 nM concentration. The control ASO with
five mismatches to the intended target did not result in in-
creased PKM1 splicing, compared to the untreated control,
and was identified in an ASOmutation screen (Supplemen-
tary Figure S2).
To test whether PKM splice-switching ASOs can induce
unintended splicing changes of exons with substantial se-
quence complementarity, we selected 140 predicted targets
and designed primers upstream and downstream of the
exon closest to the ASO-binding site for an initial RT-PCR
screen (Supplementary Table S1). Out of 140 primer pairs
tested, 32 resulted in non-specific or no amplification, and
we excluded them from further analysis. The remaining 108
primer pairs yielded correct amplicons, based on size. 22 of
them gave aberrant splice products, which we investigated
further (Supplementary Table S1). Figure 2A and Supple-
mentary Figure S3 show radioactive RT-PCR gels and iso-
form quantification of all 22 tested off-targets. Out of those
that resulted in a splicing change of >10%, 12 were com-
mon for both ASO1 and ASO2. We also detected an addi-
tional two unique off-targets for ASO1 and five unique off-
targets for ASO2. The majority of the validated off-target
splicing events resulted in skipping of constitutive exons.
In three cases (CSNK1G3, ATP5SL, PKD1), we detected
a change in relative expression of naturally occurring splice
isoforms (Figure 2A and Supplementary Figure S3). Sur-
prisingly, the mismatch control ASO (Ctrl. ASO) also in-
duced exon 12 skipping in CLIP4, as well as exon 12 inclu-
sion in CSNK1G3. Closer inspection of the sequences re-
vealed the presence of Ctrl. ASO-binding sites distinct from
the ASO1 binding site, consistent with a direct correlation
between Ctrl. ASO binding and a splicing change (Supple-
mentary Figure S4). Importantly, a different control ASO
(scrambled) used in Figure 5 did not induce exon 12 skip-
ping inCLIP4, or exon 12 inclusion inCSNK1G3, support-
ing a hybridization-dependent effect.
Next, we sought to compare the propensity of each
ASO for off-target effects. Given that each of the ASOs
used in this study has slightly different effects on PKM
splicing, we quantified the off-target effect relative to
PKM, and calculated an Off-target score (OT-score =
PSI(Off-target)/PSI(On-target), Table 2). Similar to on-target
activity, off-target splicing events increase with ASO con-
centration, confirming that the observed effects are within
the dynamic range of the assay at the 30-nM concentration
used to compare on- and off-target effects (Supplementary
Figure S1). However, potentially different EC50/Emax val-
ues between on- and off-target activity may result in dif-
ferent OT scores at higher ASO concentrations. OT-scores
>1 represent splicing changes that are greater than the
on-target effect, whereas OT-scores <1 represent splicing
changes that are smaller than the on-target effect. MOE-
modified ASOs 1 and 2 had average OT-scores of 1.08 and
1.15, respectively. In contrast, the OT-scores of cEt/DNA
ASOs 1 and 2 were statistically significantly lower (0.47 and
0.33, respectively), showing that themixed-chemistry design
is beneficial in avoiding off-target effects in vitro (Figure
2B). The OT scores of six off-targets measured in HepG2
and HT1080 cells showed some variability (Supplementary
Figure S4). However, consistent with the results we ob-
tained in U87 cells, the cEt/DNA mixed-chemistry ASOs
had reduced off-target activity, compared to the uniform-
MOE ASOs, in HepG2 and HT1080 cells (Supplementary
Figure S4).
Base-pairing of modified nucleotides in mixed-chemistry
ASOs correlates with the off-target effects
In some cases, the MOE ASO had a more robust effect on
splicing of the off-target gene than the cET/DNA (e.g.AK2
and PTOV1). In other cases (e.g., ASO1 PROM1, ASO2
UCK2), the outcome was very similar, irrespective of ASO
chemistry. To gain insight into the reason for these dif-
ferences in off-target effects, we analyzed the ASO/target
binding structures predicted by RNAhybrid, and specif-
ically looked at base-pairing of the modified bases (Fig-
ure 3A). Constrained-ethyl-modified nucleotides bind more
tightly to RNA than MOE-modified nucleotides, which
would result in excessively high Tm’s if present uniformly.
To balance the strong interactions of cEt, while maintain-
ing a melting temperature comparable to that of uniformly
modified MOE ASOs, cEt/DNA mixed-chemistry ASOs
only comprise eight cEt-modified bases (Figure 3A, high-
lighted in red). Depending on the predicted duplex struc-
ture, some predicted target binding sites have more cEt
residues engaged in base-pairing, whereas in other targets,
some cEt residues are located at mismatch positions. Bind-
ing sites with 7/8 (UCK2, ASO2) or 8/8 (PROM1, ASO1)
cEt residues engaged in base-pairing corresponded to mod-
erately lower exon skipping (UCK2 −37%) or even slightly
higher exon skipping (PROM1+2.8%), compared toMOE-
modified ASOs of the same sequence. In contrast, with six
or fewer cEt residues engaged in base-pairing, the effects on
off-target splicing were markedly reduced, compared to the
effects of MOE ASOs, likely because the overall Tm of the
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Figure 2. Validation of predicted off-targets by RT-PCR. (A) Representative autoradiographs and quantification of splice changes of exons in transcripts
to which ASOs are predicted to bind. Bar charts represent mean ± SE;N= 3; radiolabeledMspI digest of pBR322 served as size markers. PKMds (double
skipping) is an aberrant splice product that lacks both exons 9 and 10. The identities of PCR fragments labeled with an asterisk (*) were confirmed by
Sanger sequencing. (B) Quantification of the fold-difference of off-target effects, relative toPKM on-target effects, normalized to the Lipofectamine control
(OT score). An OT-score<1 indicates that the off-target effect is smaller than the on-target effect; values>1 indicate off-target effects larger than on-target
effects. The OT-score takes variable on-target activity into consideration, and thus it can be used to directly compare the off-target activity of different
ASOs. N = the number of validated off-targets for each ASO (effect > 10%); ** P < 0.01.
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Figure 3. Structures of individual ASO-binding sites. (A) Structures show the target sequence at the top (5’-3’) and the ASO sequence at the bottom (3’-5’),
as predicted (for RNA:RNA duplexes) by RNAhybrid. cEt-modified bases are highlighted in red, and the number of paired cEt bases is shown at the top
right of each field. The numbers below each structure indicate the splicing change relative to the MOE-modified ASO of the same sequence. (B) Melting
temperatures of RNA/DNA andRNA/ASO duplexes determined by high-resolutionmelting analysis. RNA (green), DNA (black),MOE (blue), cEt (red).
Data points represent mean ± SE; N = 6.
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Table 2. Off-target score of various ASO chemistries, lengths and combinations
AK2 PROM1 RER1 CLIP4 UCK2 PTOV1 CSNK1G3
ASO1-MOE 1.8 (0.14) 1.5 (0.02) 1.5 (0.21) 1.6 (0.28) 0.7 (0.08) 0.0 (0.06) 1.1 (0.10)
ASO1-cEt/DNA 0.2 (0.04) 1.5 (0.20) 0.7 (0.16) 1.0 (0.13) 0.1 (0.0) 0.1 (0.01) 0.7 (0.10)
ASO2-MOE 2.2 (0.15) 2.2 (0.13) 1.4 (0.23) 1.5 (0.21) 1.3 (0.20) 1.2 (0.09) 1.2 (0.11)
ASO2-cEt/DNA 0.3 (0.06) 0.0 (0.0) 1.1 (0.20) 0.3 (0.06) 0.9 (0.09) 0.0 (0.01) 0.5 (0.12)
ASO1-MOE/DNA 0.0 (0.0) 1.0 (0.56) 0.3 (0.06) 1.5 (0.18) 0.0 (0.0) 0.2 (0.04) 1.0 (0.37)
12mer MOE 1.3 (0.16) 0.3 (0.01) 1.1 (0.14) 1.4 (0.13) 0.1 (0.01) 1.0 (0.09) 0.0 (0.02)
MOE combination 1.0 (0.06) 0.7 (0.18) 1.0 (0.09) 0.8 (0.05) 0.7 (0.06) 0.4 (0.02) 0.5 (0.05)
Data represent mean (SE) relative to PKM.
ASO is affected a lot more by a cEt mismatch than by an
MOE mismatch.
To test the impact of cEt mismatches on the overall Tm
of the RNA/ASO duplex, we performed high-resolution
melting analysis (Figure 3B). First, we measured the Tm of
ASO2-MOEandASO2-cEt/DNA, aswell as the equivalent
DNA sequence, to a fully complementary RNA strand. As
expected, the Tm’s of the modified ASOs were significantly
higher (MOE 85.7◦C; cEt/DNA 92◦C) compared to DNA
(70.6◦C). To assess the impact of MOE versus cEt residues
on the Tm, we used the same RNA substrate and annealed
ASO1, which is shifted by three nucleotides and thus has
three fewer hybridizing nucleotides (AAT) at the 3’-end.
The overall Tm of ASO1-MOE (15-bp match) was 5.3◦C
lower, compared to the fully complementary ASO2-MOE.
However, the Tm of ASO1-cEt/DNA (15-bp match) was
6.9◦C lower, compared to ASO2-cEt/DNA (18-bp match),
confirming that non-hybridizing cEt-modified residues have
a stronger impact on the Tm than non-hybridizing MOE
residues; the difference was statistically significant (P =
0.0018) (Figure 3B).
ValidatedASOoff-targets lack shared characteristic features
One aim of this study was to identify key features that
characterize off-targets, so as to facilitate the prediction of
off-targets of new ASOs. A primary feature we looked at
was the ASO binding free energy (MFE), as predicted by
RNAhybrid. However, whenwe ranked all off-targets tested
in this study by their MFEs, only 3/10 top targets for ASO1
and 1/10 top targets for ASO2 resulted in a measurable
splicing change, indicating that MFE is a poor predictor
of off-target activity. One caveat is that the program uses
RNA-RNA hybrids for the calculations, rather than mod-
ified nucleotide-RNA. Furthermore, there was no correla-
tion betweenMFE and splicing among validated off-targets
for either ASO1 or ASO2 (Figure 4A). To see whether the
MFE obtained by RNAhybrid is a good approximation of
the actual Tmbetween anASOand its RNA target, wemea-
sured the Tm of several RNA/ASO duplexes with various
mismatches and G:U wobble base pairs (Figure 4B, Sup-
plementary Table S3). Overall, the Tm of the RNA/ASO
duplex correlated well with the predicted MFE (R2 = 0.78;
Pearson’s r = −0.89). Two of the data points (AK2 and
CLIP4) slightly deviated from the trend line. Interestingly,
both AK2 and CLIP4 RNA templates have significant pre-
dicted secondary structures (not observed in other RNA
templates used in this study), which may influence the Tm
measurements of the RNA/ASO duplex. The overall cor-
relation between MFE and measured Tm may therefore be
underestimated.
Effective splice-modulating ASOs not only need to bind
to the target RNA, but they also need to block the bind-
ing of splicing regulators. We therefore also looked at other
features of ASO-binding sites, as well as the exons to which
the ASO is predicted to bind (Figure 4 and Supplemen-
tary Figure S5). To identify relevant features for eliciting
a splicing change upon ASO binding, we statistically com-
pared all ASO-binding sites of validated off-targets (splic-
ing change > 10%) with a control group, comprising the
top 20 predicted ASO-binding sites, based on MFE, that
did not result in a splice change upon ASO treatment. Both
ASO1 and ASO2 were predicted to bind significantly more
strongly to the target sites in the control group (no detected
splicing change), compared to sites on validated off-targets
(averageMFE1.18 kcal/mol and 4.40 kcal/mol for ASO1
and ASO2 target sites, respectively (Figure 4C and D).
Given that our exon database includes exons and part
of the flanking introns, we then asked whether ASOs that
bind to exonic sequences are more likely to induce a splicing
change. We observed a trend towards exonic binding sites,
but the relative distribution of ASO-binding sites (exon, in-
tron or splice site) was not statistically different between the
off-target and control groups, both for ASO1 and ASO2
(Figure 4C and D).
Next, we asked whether the presence of RNA-binding
protein (RBP) motifs is a predictive factor in off-target
activity, considering that ASOs that interfere with exonic
splicing enhancers or silencers should be more likely to re-
sult in aberrant splicing. We used RBPmap to predict bind-
ing sites for common RBPs involved in RNA splicing reg-
ulation, within the ASO-target site. This tool includes hn-
RNPs, TRA proteins, members of the SR-protein family, as
well as others (the full list of RBPs included in this analysis
is in the Material and methods section). Interestingly, RBP
motifs were found in 85%, or 12 of 14, of predicted ASO1-
binding sites that resulted in a splicing change, compared
to 45% (9 of 20) of predicted ASO1-binding sites on exons
in the control group, for which no splicing change was de-
tected (Figure 4C). RBP motifs were also found in 76% or
13 of 17 ASO2-binding sites on mis-spliced exons, versus
60% for the control group, but this difference was not sta-
tistically significant (Figure 4D).
We also asked whether the distance between the ASO-
binding site and the nearest splice site is a predictive feature
of off-target activity. On average, ASO-binding sites that re-
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Figure 4. Characterization of ASO-binding sites. (A) The splicing change for each of the validated off-targets does not correlate with the binding energy
(MFE) (ASO1 R2 = 0.0) or is negatively correlated, with weaker interactions eliciting stronger splicing changes (ASO2 R2 = 0.16). (B) The empirically
measured Tm of ASO2 and RNA templates corresponding to off-target binding sites correlates well with the predicted MFE (R2 = 0.88, N = 6). Data
points show mean ± SEM Tm from 6 measurements. (C, G) Comparison of ASO-binding sites on validated off-targets (splicing change > 10%) with a
control group, comprising the top 20 predicted binding sites based on MFE that did not result in a splice change. Both ASO1 and ASO2 are predicted
to bind significantly more strongly to target sites in the control group, compared to sites on validated off-targets (ASO1 −30.17 kcal/mol and -31.95
kcal/mol, respectively; ASO2 −31.85 kcal/mol and −36.25 kcal/mol, respectively) Each data point indicates a unique ASO-binding site. (D, H) The
relative distribution of ASO-binding sites (exon, intron, or splice site) is not statistically different between the off-target and control groups for ASO1 and
ASO2. (E, I) Graph showing the proportion of ASO-binding sites with at least one RBP motif, as determined by RBPmap. (F, J) Chart indicating the
distance of each ASO-binding site to the nearest splice site. Negative values indicate binding sites that span exon/intron junctions. n.s., not significant; P
< 0.0056 (Bonferroni critical value) was considered to be statistically significant.
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Figure 5. Alternative strategies to reduce off-target effects in vitro. (A) ASOs used in this figure include a short 12mer ASO that overlaps both ASO1 and
ASO2, another PKM splice-switching ASO that targets intron 9 (I9), and a scrambled-sequence control ASO. (B) The effect of alternative ASOs on PKM
splice-switching. The on-target activity of MOE/DNA ASO is worse than the uniformly MOE-modified ASO1 (3.5% and 29.9% PKM1, respectively;
see Figure 2). Both the 12mer MOE (45.5% PKM1) and the combination treatment (52.3% PKM1) performed better than either ASO1 or ASO2 alone.
IndividualASOswere transfected at a final concentration of 30 nM.For the combination treatment, ASOswere transfected together, at a final concentration
of 15 nM each. (C) RadioactiveRT-PCR results of seven validated off-targets. Bar charts showmean± SE from three independent experiments. (D) Average
OT-scores for each ASO tested, for 7 different off-targets (AK2, PROM1, RER1, CLIP4, UCK2, PTOV1, CSNK1G3), compared to the ASO1 and ASO2
results. OT-scores for ASO1-MOE and ASO1-cEt/DNA serve as a point of comparison, and are the same as in Figure 2. Individual OT-scores for each
off-target are listed in Table 2. The OT-score takes variable on-target activity into consideration, and thus it can be used to directly compare the off-target
activity of different ASOs. * P < 0.05; ** P < 0.01;
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sulted in off-target splicing tended to be closer to one of the
splice sites than those that did not result in detectable splice
changes. However, as above, this trend was not significant,
due to multiple hypotheses testing.
Lastly, we did not uncover any predictive features when
looking at the larger context of mis-spliced exons, includ-
ing the length of the targeted exon, the length of the flank-
ing introns, whether the target exon is in-frame or out-of-
frame, and the total number of exons in the gene (Sup-
plementary Figure S5). Taken together, we observed posi-
tive trends for several parameters we investigated (although
none of them was statistically significant), suggesting that
the overall splicing outcome uponASO binding depends on
combinations of several features.
ASO combination enhances on-target and reduces off-target
effects in vitro
Given that cEt/DNA mixed-chemistry ASOs reduced off-
target effects for some transcripts in vitro, compared to
their uniformly MOE modified counterparts, we investi-
gated additional strategies to increase the specificity of
splice-switching ASOs targeting PKM. We therefore de-
signed additional ASOs, including an MOE/DNA mixed-
chemistry ASO and a short 12mer ASO.We also found that
ASOs targeting splicing-regulator binding sites in PKM in-
tron 9 induce splice-switching, albeit to a lesser extent than
exon 10ASOs (manuscript in preparation), and so we tested
a uniformly modified MOE ASO targeting PKM intron 9,
in combination with ASO2 (Figure 5A).
TheMOE/DNAASOhad a significantly lower on-target
activity than the equivalent fullymodifiedMOEASO (4.1%
and 30.6% PKM1, respectively, Figure 5B). We also ob-
served a reduced OT-score, which is comparable to the ef-
fect seen with cEt/DNA mixed chemistry ASOs. However,
given the low efficacy of the MOE/DNA ASO, it is diffi-
cult to attribute the apparent increase in specificity to ASO
chemistry alone (Figure 5C).
Short 8–13mer ASOs, although less potent, have been
used successfully in vitro for splice modulation (28,29). We
hypothesized that short ASOsmay bemore sensitive tomis-
matches than 18merASOs, which show some resistance that
depends on the mismatch position (Supplementary Fig-
ure S2). We therefore designed a uniformly MOE-modified
PKM-targeting 12mer ASO that overlaps with both ASO1
and ASO2 (Figure 5A) and tested its on- and off-target ac-
tivities. Interestingly, we observed a strong reduction of the
OT-score of the shorter ASO with a subset of off-targets
(PROM1,RER1 andCSNK1G3; Figure 5). Sequence align-
ment of the 12mer ASO with our exon/intron database
revealed one perfect match (EXD3; not expressed in U87
cells), as well 34 additional matches containing a single G:U
base pair. However, given that the 12mer sequence is con-
tained in both the ASO1 and ASO2 sequences, the parent
ASOs would presumably bind to a similar extent, resulting
in largely overlapping off-target activity.
The last strategywe tested to increase on-target specificity
was to use a combination of ASOs targeting distinct regula-
tory elements of the same splicing event. The complex reg-
ulation of PKM alternative splicing allows targeting differ-
ent sites from exon 9 to exon 10 to efficiently induce PKM2
to PKM1 splice-switching (14,18). For PKM, these sites in-
clude a secondary regulatory region in exon 10, as well as a
region in intron 9 (manuscript in preparation).We reasoned
that the use of a second ASO targeting the same splicing
event may allow lowering the concentration of each indi-
vidual ASO, and could perhaps show synergy, potentiating
the effects of single ASOs. We used an intron 9 MOE ASO
in combination with ASO2-MOE, and transfected cells at a
final concentration of 15 nM of each ASO. In combination,
theseASOs induced strongerPKM splice-switching (52.9%)
than 30 nM intron ASO2-MOE alone (32.1%). The intron 9
ASO is less potent than ASO1 or ASO2-MOE (manuscript
in preparation). Importantly, off-target effects were signif-
icantly reduced when the ASOs were used in combination
(Figure 5).
Strategically placed mismatches can be used to reduce spe-
cific off-target activity
To investigate whether mismatches can be used to reduce
the activity on specific off-targets, we tested a sequence vari-
ant of ASO1, with 5 mismatches to PKM at the 3’-end of
the ASO (Figure 6A and Supplementary Figure S2). The
effect on PKM splice switching in transfected U87 cells
was comparable to that of the fully complementary par-
ent ASO (Supplementary Figure S2). The effect on off-
target activity, however, depended on the target and lo-
cation of mismatches (Figure 6B). We tested four differ-
ent mis-splicing events induced by ASO1 (PTOV1, RER1,
UCK2 and PROM1). The parent ASO is predicted to bind
with mismatches to PTOV1 and RER1 targets; Therefore,
changing the ASO sequence at the 3’-end did not signifi-
cantly reduce off-target activity for these two targets (Fig-
ure 6A). In contrast, targets predicted to hybridize with the
ASO at the 3’-end (UCK2 and PROM1) were negatively
affected by the mutant ASO. As a result, we observed a
statistically significant reduction in off-target mis-splicing
(Figure 6B). In conclusion, strategically placed mismatches
could therefore be used to prevent a particular off-target
event, while maintaining on-target activity.
Free uptake reduces off-target effects of splice-switching
ASOs
In vitro, ASOs are routinely delivered by lipid transfection
directly into the cytoplasm, bypassing natural uptake and
endosomal-release pathways. In addition, cationic lipids are
known to enhance nucleic acid hybridization (30). Alterna-
tively, in some cell lines ASOs can also be delivered by free
uptake (31–33). However, only small quantities of ASOs
delivered by free uptake escape the endosome and reach
the target in the nucleus. Thus, higher ASO concentrations
are required, and the effects on RNA splicing are usually
observed a few days later, compared to lipid transfection.
We tested whether the delivery method (lipid transfection
vs. free-uptake) affects off-target splicing of six validated
events (AK2,CLIP4, PROM1, PTOV1,RER1 andUCK2).
U87 cells were exposed to ASOs in the medium at con-
centrations up to 30 M for 5 days. PKM on-target splic-
ing increased in a concentration-dependent manner, with
ASO2-cEt/DNAperforming better thanASO2-MOE (Fig-
ure 7). In contrast, mis-splicing of off-targets was markedly
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Figure 6. ASO mismatches differentially affect off-target splicing. (A)
MOE-ASOs used to compare the effects of mismatches on off-target splic-
ing includeMOE-ASO1 (fully complementary to PKM) and an ASO with
five mismatches (highlighted in red). Mismatches at the 3’-end of the ASO
have a minimal effect on PKM splice switching (see Supplementary Fig-
ure S1). (B) ASO/RNA duplex structures (left) and quantification of the
resulting splice change in U87 cells (right). ASOs were delivered by lipid
transfection at a final concentration of 30 nM. Splicing changes were ana-
lyzed 48 hrs post-transfection. Bar graphs represent mean ± SE; N = 3; *
P < 0.05; ** P < 0.01;
reduced when ASOs were delivered by free uptake, com-
pared to lipid transfection. The average OT-score measured
for ASO2-MOE delivered by free uptake was significantly
lower than by lipid transfection (0.7 and 1.8, respectively;
2.6 fold; P= 0.002). Off-target activity of ASO2-cEt/DNA
was not detectable with 4/6 targets. However, the 5-fold
reduction of OT-score compared to lipid transfection (0.1
and 0.5, respectively), was not statistically significant (P =
0.068).
To test off-target activity of PKM ASOs in vivo,
we used a receptor/ligand ASO delivery system (27).
Tri-antennary N-acetyl galactosamine (GN3)-conjugated
MOE and cEt/DNA ASOs were delivered subcutaneously
to animals bearing U87 xenografts expressing the GN3-
receptor (ASGP-R1). We only observed a significant in-
crease inPKM1 levels in the animals treated with the higher
affinity cEt/DNA ASO (Supplementary Figure S6B). We
then tested the same off-target splicing events as in our
in vitro free-uptake experiment (AK2, CLIP4, PROM1,
PTOV1, RER1 and UCK2) and found increased levels of
RER1 exon 6 skipping, similar to the results in the free-
uptake experiments (Supplementary Figure S6B). Aberrant
splicing of UCK2 (observed by free uptake in vitro) was
not detectable in vivo. Off-target scores comparing delivery
methods in vitro and in vivo are listed in Table 3. This set
of results, although limited to one ASO, suggests that off-
target mis-splicing is of greater concern in in vitro experi-
ments, compared to applications for which ASOs are typi-
cally delivered by natural uptake mechanisms, including in
vivo.wpt
DISCUSSION
Splice-modulating ASOs can be highly specific, and de-
pending on their length, can be designed to only match
a single complementary site in the transcriptome. Even if
there are additional ASO-binding sites present, it is un-
likely that they overlap with a critical sequence element in-
volved in splice regulation, such as a splicing enhancer or si-
lencer. In this study, we investigated off-target mis-splicing
events of splice-modulating PKMASOs, and identified sev-
eral splicing changes in constitutive exons, as well as alter-
native splice isoforms of ASO off-targets. All of the off-
target splicing events appear to be sequence-specific, as in
most cases neither a mismatch control ASO nor a scram-
bled ASO had an effect on these off-targets. In both cases in
which the control ASO did affect the exon of interest, there
were additional binding sites for the control ASO, support-
ing the notion that the observed effects are hybridization-
dependent.
Closer inspection of ASO/RNA duplex structures re-
vealed that in general, G:Uwobble base pairs, terminal mis-
matches, and short internal loops and bulges are readily
tolerated. For one of the off-targets (FRYL), we detected
multiple exon-sipping events, even though only 12/18 nu-
cleotides of ASO2 are predicted to base-pair with the tar-
get, two of which are wobble base pairs. This observation
underscores the importance of choosing the right tool to
identify sequence complementarities in the transcriptome.
A BLAST search, even optimized for short sequences, only
results in a limited number of hits, based on sequence align-
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Figure 7. Free uptake reduces off-target effects in vitro. (A) U87 cells were exposed to ASO2-MOE and ASO2-cEt/DNA (0–30 M) in the culture medium
for 5 days. Autoradiographs show representative results, and bar charts showmean± SE from three independent experiments. (B) Average off-target scores
of all 6 tested off-target splicing events (AK2, CLIP4, PROM1, PTOV1, RER1, and UCK2), relative to PKM, at 30 M. Error bars represent mean ± SE
OT-score of all tested off-targets. n.s. not significant; * P < 0.05; ** P < 0.01
Table 3. Off-target score of ASO2-cEt/DNA delivered in vitro and in vivo
% PKM1 AK2 PROM1 RER1 CLIP4 UCK2 PTOV1
Transfection in vitro 34.0 (2.9) 0.3 (0.06) 0.0 (0.0) 1.1 (0.20) 0.3 (0.06) 0.9 (0.09) 0.0 (0.01)
Free uptake in vitro 18.0 (1.8) 0.0 0.0 0.1 (0.01) 0.0 0.1 (0.0) 0.0
s.c. delivery in vivo* 11.7 (1.3) 0.0 not expr. 0.3 (0.07) 0.0 0.0 0.0
Data represent mean (SE) relative to PKM; s.c. subcutaneous; *GN3-conjugated ASO2-cEt/DNA.
ment. However, this search algorithm ignores G:U base-
pairing, and the results seldom have internal mismatches,
which are commonly found in natural RNA structures, lim-
iting its value for ASO target prediction.
We therefore used RNAhybrid, a program originally de-
signed to predict miRNA target sites, based on RNA sec-
ondary structures. The advantage of RNAhybrid is that the
number of hits and the cutoff can be manually set, result-
ing in extensive lists that can be sorted and annotated to fit
the need of the user. However, the predicted structures and
predicted minimum free energy of the interaction are based
on RNA/RNA binding, which at best provides only an ap-
proximation of the binding energy of uniformly modified
ASO interactions with RNA. For mixed-chemistry ASOs
with high affinity cEt residues mixed with DNA residues,
the resulting duplex structures, and by extension the bind-
ing energies, may be substantially different fromwhat is pre-
dicted for RNA-RNA duplexes. Unfortunately, alignment
algorithms that take into consideration ASO modifications
in mixed-chemistry ASOs do not yet exist, and are likely
crucial for accurately predictingASObinding affinity to tar-
get sites. In addition, sequence-based affinity calculations
ignore the larger context of secondary structures and RNA-
binding proteins, both of which are known to influence the
off-target activity of gapmer ASOs (34).
As mentioned above, even if there is an adequate esti-
mate of binding affinity, binding itself is not enough to in-
duce a splice change, for the same reason that not every
ASO designed against a target is effective in changing its
splicing. In our study, we identified many unaffected tar-
get sites with predicted binding affinities that were signifi-
cantly stronger than those of validated off-target sites. We
tested various hypotheses to identify features with strong
predictive value. Overall, our results did not point to any
dominant individual feature; however, we observed several
trends. For example, ASO-binding sites in exons harboring
RBP motifs tended to be more likely to induce off-target
mis-splicing. We also detected a slightly higher proportion
of unaffected off-target sites located on out-of-frame exons,
which result in premature termination codons and poten-
tially in nonsense-mediated mRNA decay (NMD). Some
NMDtargets are rapidly degraded, andmay not be detected
as an alternative splice isoform by RT-PCR, potentially
masking unidentified off-target splicing events. A compre-
hensiveRNA-sequencing study, including protein-synthesis
inhibitors to abrogate NMD, might help address whether
predictive features do exist, and to what extent NMD hides
some mis-splicing events.
The present study addresses off-target effects of a lim-
ited number of PKM ASOs. To derive universal rules for
off-target prediction, it will be desirable to study additional
ASOs to other targets, in multiple different cell lines. Test-
ing additional ASOs would also address whether the po-
tential secondary structure of the ASO itself, the base com-
position, or the GC-content, play a role in the extent of
off-target activity. In addition to effects on RNA splicing,
ASOsmay also affect other steps of gene expression, includ-
ing transcription, RNA processing, export and turnover,
and translation. ASOs are very effective translation in-
hibitors when targeting the start codon or 5’UTR of a tran-
script, and are commonly used for targeted knockdown
of genes in zebrafish (35,36). In contrast, Liang and col-
leagues showed that someASOs targeting the 5’UTRof cer-
tain mRNAs can increase their translation (37). Splicing-
independent off-target effects may be relevant for some
splice-modulating ASOs, but we did not address them in
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this study. Potential effects on translation would require dif-
ferent detection methods. Finally, ASOs could potentially
also bind to, and neutralize, miRNAs or their precursors, or
interfere with lncRNA processing or function, which could
in turn have global effects on gene expression.
Given that we are currently unable to robustly predict
off-target effects on splicing, our focus shifted to identify-
ing strategies to reduce off-target activity. Both on- and off-
target splicingwere concentration-dependent, prompting us
to use two ASOs in combination, each at half the concen-
tration. Alternative splicing events, the primary target of
splice-modulatingASOs, are often regulated bymultiple en-
hancer and silencer elements. PKM exon 10 splicing, for ex-
ample, is regulated by multiple elements located in intron 9
and exon 10 (18,38) (manuscript in preparation). ASOs de-
signed against intron 9 and exon 10, used in combination,
increased PKM splice switching, while reducing off-target
effects. These results reinforce the notion that the off-target
effects observed in this study are hybridization-dependent,
rather than a secondary effect caused by modulating PKM
isoforms and the consequent alterations in cell physiology.
Thus, ASO combinations can be an effective way to increase
target specificity. In cases in which usingASO combinations
is not feasible, we showed that introducing mismatches can
also be used to avoid some off-target splicing effects, while
maintaining on-target activity. However, in either scenario,
every additional ASO may have new, non-overlapping sets
of off-target sites, adding an extra layer of complexity.
Another strategy we explored to increase ASO specificity
was to use a shorter 12mer MOE ASO, with a sequence
that overlaps both 18mer ASOs used in this study. Com-
pared to ASO2-MOE, the 12mer ASO resulted in a strong
reduction of off-target activity for a subset of targets. How-
ever, we did not screen for 12mer ASO-binding sites specif-
ically, and may well have missed off-target activity for tar-
gets we did not test byRT-PCR.Ultrashort ASOs have been
used successfully, both in vitro and in vivo. For example, uni-
formly modified 8mer LNA ASOs have been used to block
microRNA seed regions, without any obvious effects on off-
target transcription or translation inhibition (39). In other
studies, a 2’-O-methyl-modified 8mer ASO was used both
in vitro (28) and in vivo (40) to induce SMN2 exon 7 inclu-
sion. Considering that a short 8–12nt target site can be suffi-
cient to elicit an efficient splicing change, using longerASOs
(although more potent) could theoretically decrease their
specificity when ASOs are present in excess. Woolf et al. cal-
culated the number of perfectly complementary 10mer sites
in a 2 × 107 base RNA pool to be 19 for any given 10mer
ASO, not considering G:U base pairing (4). For a 15mer
containing 6 unique 10mer sequences, the number of com-
plementary sites in the RNA pool increases to 210.
As expected, single-nucleotide mismatches appear to af-
fect short ASOs more severely than longer ASOs: we
showed that depending on the mismatch location, uni-
formly MOE-modified 18mer PKM ASOs with five mis-
matches can still induce efficient splice switching; in con-
trast, single-nucleotide mismatches of LNA nucleotides
introduced at various positions of a 13mer LNA/DNA
mixed-chemistry ASO designed to enhance SMN exon 7
inclusion––even at the 3’ end of theASO––significantly low-
ered inclusion efficiency (29). Even though longer ASOs
may be more resistant to mismatches, and hybridize with
off-target sequences in vitro, longer sequences might also
provide an advantage at the lower, non-saturating concen-
trations typically obtainable in vivo. However, any such ad-
vantage with respect to their effect on off-target activity in
vivo has yet to be determined, but is beyond the scope of
this study.
Another important point raised in this study is that the
mode of delivery of ASOs influences the extent of off-target
splicing. ASOs are typically delivered in vitro by lipid trans-
fection, and directly reach the cytoplasm. From there, they
can readily reach the nucleus to engage the pre-mRNA tar-
get. In contrast, ASOs delivered in vivo and by free up-
take in vitro, are internalized by endocytosis and to a small
extent by micropinocytosis (41). Only a fraction of ASOs
trapped in endosomes escapes, resulting in a much lower
amount of ASO available to engage the target. Our results
show that ASOs are more specific towards on-target splice-
switching when delivered by free-uptake and in vivo, pos-
sibly because of more gradual and consistent internaliza-
tion at lower concentrations, thus avoiding excess amounts
of ASO in the nucleus, relative to the pre-mRNA target.
Off-target mis-splicing may therefore be a greater issue in
cell culture than in vivo applications. Given that lead ASOs
are usually identified in cell-based screening assays, often by
lipid transfection, care has to be taken not to misinterpret
results that may stem from off-target activity. When feasi-
ble, mixed-chemistry ASOs, ASO combinations, or targeted
mismatches can be used to minimize off-target effects. Fur-
thermore, when appropriate, functional assays should in-
clude cDNA rescue experiments, to verify that the observed
ASO activity is on-target.
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